Many patients suffering from depressive disorders are refractory to treatment with currently available antidepressant medications, while many more exhibit only a partial response. These factors drive research to discover new pharmacological approaches to treat depression. Numerous studies demonstrate evidence of inflammation and elevated oxidative stress in major depression. Recently, major depression has been shown to be associated with elevated levels of DNA oxidation in brain cells, accompanied by increased gene expression of the nuclear base excision repair enzyme, poly(ADP-ribose) polymerase-1. Given these findings and evidence that drugs that inhibit poly(ADP-ribose) polymerase-1 activity have antiinflammatory and neuroprotective properties, the present study was undertaken to examine the potential antidepressant properties of poly(ADP-ribose) polymerase inhibitors.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Ordway, Gregory A.; Szebeni, Attila; Hernandez, Liza J.; Crawford, Jessica D.; Szebeni, Katalin; Chandley, Michelle J.; Burgess, Katherine C.; Miller, Corwin; Bakkalbasi, Erol; and Brown, Russell W.. 2017. Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models. International Journal of Neuropsychopharmacology. Vol.20(12). 994-1004. https://doi.org/10.1093/ijnp/pyx068 ISSN: 1461-1457